Trial Profile
Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors Shanghai Zerun Biotechnology Co
- 12 Apr 2023 Status changed from recruiting to completed.
- 19 Apr 2016 New trial record